Pan Tumor Rollover Study
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Status
- RECRUITING
- Phase
- PHASE1
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
- Status
- RECRUITING
- Phase
- PHASE2
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
- Status
- UNKNOWN
- Phase
- PHASE1
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1